Targeting Mitochondria for Neuroprotection in Parkinson's Disease
- 1 May 2012
- journal article
- review article
- Published by Mary Ann Liebert Inc in Antioxidants and Redox Signaling
- Vol. 16 (9), 965-973
- https://doi.org/10.1089/ars.2011.4419
Abstract
Significance: Several genetic causes of familial Parkinson's disease (PD) have now been identified and include mutations of genes encoding mitochondrial proteins. Mitochondrial complex I toxins can induce dopaminergic cell death and produce a parkinsonian state. Importantly, defects of mitochondrial function have been identified in postmortem substantia nigra from pathologically proven cases of PD. Recent Advances: These observations provide compelling evidence to support the notion that mitochondria play an important role in the pathogenesis of PD. Thus, targeting mitochondrial function to delay or prevent neuronal cell death would represent a logical means to modify the course of this disease. Several attempts have already been made in this respect, and have been tested in clinical trial. Critical Issues: To date, there is no unequivocal evidence for an effective intervention to slow the disease. However, several novel mitochondrial targets are now emerging, including the potential to manipulate the mitochondrial pool to maintain function via biogenesis and mitophagy. Future Directions: This development in drug targets needs to be supported by a parallel improvement in clinical trial design to be able to detect a neuroprotective or disease-modifying effect over a reasonable time scale. Antioxid. Redox Signal. 16, 965–973.Keywords
This publication has 84 references indexed in Scilit:
- Chaperone-Mediated Autophagy Markers in Parkinson Disease BrainsArchives of Neurology, 2010
- Loss of Anion Transport without Increased Sodium Absorption Characterizes Newborn Porcine Cystic Fibrosis Airway EpitheliaCell, 2010
- Mitochondrial dynamics in cell death and neurodegenerationCellular and Molecular Life Sciences, 2010
- Genetic variability in the mitochondrial serine proteaseHTRA2contributes to risk for Parkinson diseaseHuman Mutation, 2008
- Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trialNeurology, 2006
- Mitochondria: Dynamic Organelles in Disease, Aging, and DevelopmentCell, 2006
- Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson DiseaseThe Journal of Clinical Pharmacology, 2005
- The Sir2 Family of Protein DeacetylasesAnnual Review of Biochemistry, 2004
- Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegilineNeuroscience Letters, 2003
- Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical InvolvementJournal of Neurochemistry, 1992